• Pickett MJ, Hollis DG, Bottone EJ. Miscellaneous gram-negative bacteria In: Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of clinical microbiology, 5th edn. Washington: DC, 1991:410-28.
• Gahrn-Hansen B, Alstrup P, Dessau R, et al. Outbreak of infection with Achromobacter xylosoxidans from contaminated intravascular pressure transducers. J Hosp Infect. 1988;12:1-6. doi: 10.1016/0195-6701(88)90115-6.
• Stobbelaar K, Van Hoorenbeeck K, Lequesne M, et al. Sepsis Caused by Achromobacter xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease. Am J Case Rep. 2016;17:562-6. doi: 10.12659/AJCR.896577.
• Lambiase A, Catania MR, Del Pezzo M, et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2011;30:973-80. doi: 10.1007/s10096-011-1182-5
• Spilker T, Vandamme P, Lipuma JJ. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros. 2013;12:298-301. doi: 10.1016/j.jcf.2012.10.002
• Coward A, Kenna DTD, Perry C, et al. Use of nrdA gene sequence clustering to estimate the prevalence of different Achromobacter species among Cystic Fibrosis patients in the UK. J Cyst Fibros. 2016;15:479-85. doi: 10.1016/j.jcf.2015.09.005
• Spicuzza L, Sciuto C, Vitaliti G, et al. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis. 2009;28:191-5. doi: 10.1007/s10096-008-0605-4.
• Pereira RHV, Carvalho-Assef AP, Albano RM, et al. Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients. J Clin Microbiol. 2011;49:3649-51. doi: 10.1128/JCM.05283-11.
• De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans infection in Cystic Fibrosis: prevalence and clinical relevance. J Cyst Fibros. 2007;6(1):75-8. doi: 10.1016/j.jcf.2006.05.011.
• Pereira RHV, Leao RS, Carvalho-Assef AP, et al. Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis. Epidemiol Infect. 2017;145:600-6. doi: 1017/S0950268816002624.
• Molin S, Tolker-Nielsen T. Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilization of the biofilm structure. Curr Opin Biotechnol. 2003;14:255-61. doi: 10.1016/S0958-1669(03)00036-3.
• Traglia GM, Almuzara M, Merkier AK, et al. Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer. Curr Microbiol. 2012;65:673-8. doi: 10.1007/s00284-012-0213-5.
• Saiman L, Chen Y, Tabibi S, et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol. 2001;39:3942-5. doi: 10.1128/JCM.39.11.3942-3945.2001.
• Rolston KV, Messer M. The in-vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 40 antimicrobial agents. J Antimicrob Chemother. 1990;26:857-60. doi: 10.1093/jac/26.6.857.
• Wang M, Ridderberg W, Hansen CR, et al. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J Cyst Fibros. 2013;12:638-43. doi: 10.1016/j.jcf.2013.04.013.
• Atalay S, Ece G, Samlioglu P, et al. Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans. Scand. J Infect Dis. 2012;44:798-801. doi:10.3109/00365548.2012.664780.
• Saeed A, Bosch A, Bettiol M, Nossa González DL, Erben MF, Lamberti Y. Novel guanidine compound against multidrug-resistant cystic fibrosis-associated bacterial species. Molecules. 2018;23(5):1158. doi: 10.3390/molecules23051158.
• Surendran-Nair M, Lau P, Liu Y, Venkitanarayanan K. Efficacy of selenium in controlling Acinetobacter baumannii associated wound infections. Wound Medicine. 2019;26(1):100165. doi: 10.1016/j.wndm.2019.100165.
• Abbott IJ, Peleg AY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med. 2015;36:99-110. doi: 10.1055/s-0034-1396929
• Döring G, Flume P, Heijerman H, Elborn JS. Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros. 2012;11:461-479. doi: 10.1016/j.jcf.2012.10.004
• Gade SS, Nørskov-Lauritsen N, Ridderberg W. Prevalence and species distribution of Achromobacter sp. cultured from cystic fibrosis patients attending the Aarhus centre in Denmark. J Med Microbiol. 2017;66:686-9. doi: 10.1099/jmm.0.000499.
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty-fourth informational supplement M100-S24. 2014.
• Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V, ed. Antibiotics in Laboratory Medicine, Baltimore: Williams and Wilkins Inc, 1996:296-329.
• Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis. 1981;3:28-37. doi:10.1093/clinids/3.1.28
• National Committee for Clinical Laboratory Standards NCCLS. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne: PA, USA. 1999.
• Ozbek B, Otuk G. Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa. Chemother. 2009;55:446-50. doi: 10.1159/000265128.
• Ozbek B, Şentürk A. Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii. Chemother. 2010;56:466-71. doi: 10.1159/000321015.
• Gaibani P, Lombardo D, Lewis RE, et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother. 2014;69:1856-65. doi: 10.1093/jac/dku065.
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918-951. doi: 10.1164/rccm.200304-505SO.
• Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother. 2006;50:819-21. doi: 10.1128/AAC.50.2.819-821.2006.
• Parkins MD, Elborn JS. Newer antimicrobial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother. 2010;65:1853-61. doi: 10.1093/jac/dkq245.
• Liu WD, Shih MC, Chuang YC, Wang JT, Sheng WH. Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia. J Microbiol Immunol Infect. 2019;52:788-95. doi: 10.1016/j.jmii.2019.04.008.
• Jones RN, Bell JM, Sader HS, Turnidge JD, Stilwell MG. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Diagn Microbiol Infect Dis. 2009;63:434-9. doi: 10.1016/j.diagmicrobio.2009.01.025.
• Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 2004;54:144-54. doi:10.1093/jac/dkh298.
• Bustamante CI, Drusano GL, Tatem BA, Standiford HC. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984;26:678-82. doi: 10.1128/aac.26.5.678
• Hanberger S, Vogelman B, Craig WA. The in vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother. 1986;18:67-73. doi: 10.1093/jac/18.supplement_e.67.
• Hanberger H, Nilsson LE, Nilsson M, Maller R. Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis. 1991;10:927-34. doi: 10.1007/BF02005446.
• Nadler HL, Pitkin DH, Sheikh W. The postantibiotic effect of meropenem imipenem on selected bacteria. J Antimicrob Chemoth. 1989;24:225-31. doi: 10.1093/jac/24.suppl_a.225.
• Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosaIsolates from Patients with Cystic Fibrosis. Antimicrob Agents Chemother. 2001;45:781-5. doi: 10.1128/AAC.45.3.781-785.2001.
• Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis. 2012;56:398-404. doi: 10.1093/cid/cis909.
• Van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2000;44:9439. doi: 10.1128/aac.44.4.943-949.2000.
• Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftaroline against Gram-positive organisms. Antimicrob Agents Chemother. 2009;53:4537-9. doi: 10.1128/AAC.00785-09
• Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents. 2005;25:95-109. doi: 10.1016/j.ijantimicag.2004.10.002.
• Houston AK, Jones RN. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. Diagn Microbiol Infect Dis. 1994;8:57-59. doi: 10.1016/0732-8893(94)90134-1.
• Minguez F, Ramos C, Barrientos S, Loscos A, Prieto J. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones. Chemother. 1991;7:420-5. doi: 10.1159/000238889.
• Spangler SK, Bajaksouzian S, Jacobs MR, Appelbaum PC. Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 Gram-positive and-negative bacteria. Antimicrob Agents Chemother. 2000;44:186-9. doi: 10.1128/aac.44.1.186-189.2000.
• Hu Y, Zhu Y, Ma Y, et al. Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans. Antimicrob Agents Chemother. 2015; 59:1152-61. doi: 10.1128/AAC.04260-14.
• Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF. Achromobacter xylosoxidans Bacteremia: Report of Four Cases and Review of the Literature. Clin Infect Dis. 1996;23:569-576. doi: 10.1093/clinids/23.3.569.
• Duez JM, Hadjiat-Savioz M, Siebor E, et al. In Vitro Synergistic Activity of Combined Piperacillin and Tobramycin Against Clinical Strains of Achromobacter xylosoxidans. J Chemotherapy. 2010;22:139-41. doi: 10.1179/joc.2010.22.2.139
• Almuzara M, Limansky A, Ballerini V, et al. In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest, and agar dilution methods. Int J Antimicrob Agents. 2010;35(1):68-71. doi: 10.1016/j.ijantimicag.2009.08.015.
• Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev. 2004;28(5):519-42. doi: 10.1016/j.femsre.2004.04.001
• Morita Y, Tomida J, Kawamura Y. Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol. 2014;4:422. doi: 10.3389/fmicb.2013.00422.
• Athamna A, Athamna M, Medlej B, Bast DJ, Rubinstein E. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J Antimicrob Chemother. 2004;53(4):609-15. doi: 10.1093/jac/dkh130.
• Jones RN, Ferraro MJ, Reller LB, et al. Multicenter Studies of Tigecycline Disk Diffusion Susceptibility Results when Testing Acinetobacter spp. J Clin Microbiol. 2006. doi: 10.1128/JCM.01588-06.

Vancouver

Damar-Çelik D, Özbek-Çelik B, Nørskov-Lauritsen N. Post-antibiotic Effect of Various Antibiotics against Achromobacter xylosoxidans Strains Isolated from Patients with Cystic Fibrosis. J Clin Exp Invest. 2020;11(4):em00750. https://doi.org/10.5799/jcei/8294

APA

Damar-Çelik, D., Özbek-Çelik, B., & Nørskov-Lauritsen, N. (2020). Post-antibiotic Effect of Various Antibiotics against Achromobacter xylosoxidans Strains Isolated from Patients with Cystic Fibrosis. Journal of Clinical and Experimental Investigations, 11(4), em00750. https://doi.org/10.5799/jcei/8294

AMA

Damar-Çelik D, Özbek-Çelik B, Nørskov-Lauritsen N. Post-antibiotic Effect of Various Antibiotics against Achromobacter xylosoxidans Strains Isolated from Patients with Cystic Fibrosis. J Clin Exp Invest. 2020;11(4), em00750. https://doi.org/10.5799/jcei/8294

Chicago

Damar-Çelik, Damla, Berna Özbek-Çelik, and Niels Nørskov-Lauritsen. "Post-antibiotic Effect of Various Antibiotics against Achromobacter xylosoxidans Strains Isolated from Patients with Cystic Fibrosis". Journal of Clinical and Experimental Investigations 2020 11 no. 4 (2020): em00750. https://doi.org/10.5799/jcei/8294

Harvard

Damar-Çelik, D., Özbek-Çelik, B., and Nørskov-Lauritsen, N. (2020). Post-antibiotic Effect of Various Antibiotics against Achromobacter xylosoxidans Strains Isolated from Patients with Cystic Fibrosis. Journal of Clinical and Experimental Investigations, 11(4), em00750. https://doi.org/10.5799/jcei/8294

MLA

Damar-Çelik, Damla et al. "Post-antibiotic Effect of Various Antibiotics against Achromobacter xylosoxidans Strains Isolated from Patients with Cystic Fibrosis". Journal of Clinical and Experimental Investigations, vol. 11, no. 4, 2020, em00750. https://doi.org/10.5799/jcei/8294